论文部分内容阅读
目的分析血液透析并发症经左卡尼汀联合重组人促红细胞生长素及铁剂治疗的临床效果。方法纳入实验病例来自我院2013年2月~2015年2月收治的行血液透析伴随并发症的患者46例,将其随机分为两组,每组23例,对照组患者仅用重组人促红细胞生长素及铁剂治疗,干预组患者重组人促红细胞生长素及铁剂治疗同时联合左卡尼汀。评估两组患者并发症缓解情况、血液指标情况。结果相关数据进行卡方检验,干预组患者临床症状中,低血压、心悸、乏力、胸闷4项均消失,肌肉痉挛、心律失常减少,对照组低血压、心悸、乏力、肌肉痉挛、胸闷、心律失常均有改善,但改善幅度低于干预组,比较有统计学差异(P<0.05)。相关数据进行t检验,两组患者治疗后血液指标中红细胞比容、血红蛋白、血清白蛋白、甘油三酯和血清铁蛋白均改善,跟治疗前比较有统计学差异(P<0.05)。但治疗后干预组改善跟对照组相比更为显著(P<0.05)。治疗组临床症状和血液指标改善后能够维持相对平稳性,波动性小。结论血液透析并发症经左卡尼汀联合重组人促红细胞生长素及铁剂治疗的临床效果确切,可有效缓解和消除临床并发症,改善血液指标,改善患者生活质量和预后,可推广应用。
Objective To analyze the clinical effect of levocarnitine combined with recombinant human erythropoietin and iron on hemodialysis complications. Methods A total of 46 patients with hemodialysis with complications from our hospital from February 2013 to February 2015 were enrolled in this study. They were randomly divided into two groups (n = 23 in each group). Patients in the control group Erythropoietin and iron treatment, intervention group patients with recombinant human erythropoietin and iron treatment combined with levocarnitine. To assess the two groups of patients with complications, blood parameters. Results The data were analyzed by chi-square test. Among the clinical symptoms of the intervention group, 4 items of hypotension, palpitations, fatigue, chest tightness disappeared, muscle spasms and arrhythmia were reduced, and hypotension, palpitations, fatigue, muscle spasms, Disorders were improved, but the improvement rate was lower than the intervention group, there was a statistically significant difference (P <0.05). The t-test showed that the hematocrit, hemoglobin, serum albumin, triglyceride and serum ferritin were all improved in the blood indexes after treatment in both groups, with statistical significance (P <0.05). However, the intervention group after treatment improved compared with the control group was more significant (P <0.05). After treatment, the clinical symptoms and blood parameters improved to maintain a relatively stable, less volatile. Conclusion The complication of hemodialysis by L-carnitine combined with recombinant human erythropoietin and iron treatment has the exact clinical effect, which can effectively relieve and eliminate clinical complications, improve blood parameters, improve patients’ quality of life and prognosis, and can be popularized and applied.